期刊文献+

革兰阴性菌感染新生儿血浆脂多糖测定临床意义 被引量:6

原文传递
导出
摘要 目的探讨脂多糖测定在革兰阴性菌感染新生儿早期诊断中的意义。方法 129例NICU患儿,入院后采集标本行细菌培养,并依据细菌培养结果分为革兰阴性菌感染新生儿79例(观察组),培养阴性新生儿50例(对照组),比较2组入院第1、3天血浆脂多糖(lipopolysaccharide,LPS)、降钙素原(procalcitonin,PCT)水平;以白细胞计数>20×109/L为标准,将对照组分为白细胞计数正常与异常组,分析白细胞计数与LPS水平的关系。结果观察组入院第1、3天LPS及PCT水平高于对照组(P<0.01);对照组白细胞计数正常与异常患者PCT水平分别为(1.73±1.62)、(1.65±1.55)ng/L,差异无统计学意义(P>0.05)。结论检测LPS可在细菌培养结果空白期为革兰阴性菌感染诊断提供支持,且其检测结果不受白细胞计数干扰。
出处 《中华实用诊断与治疗杂志》 2013年第6期623-624,共2页 Journal of Chinese Practical Diagnosis and Therapy
基金 广州市医药卫生科技项目(2012A011040024)
  • 相关文献

参考文献7

二级参考文献25

  • 1陈远华,徐德祥,王华,赵磊,王剑萍,魏凌珍,孙美芳.褪黑素保护细菌脂多糖引起的小鼠宫内胎儿死亡和生长发育迟缓[J].安徽医科大学学报,2006,41(4):368-371. 被引量:12
  • 2Bone RC,Balk RA,Cerra FB. ACCP/SCCM definitions for sepsis and organ failure guidelines for the use of innovative therapies in sepsis[J]. Chest, 1992,101:1644- 1655.
  • 3Joan M. The role of C reactive protein in the evaluation and management of infants with suspected sepsis[J].Adv Neonatal Care,2003,3(1):3 -13.
  • 4Povoa P, Almeida E, Moreira P,et al. C-reactive protein as an in dicator of sepsis[J]. Intensive Care Med, 2008, 24: 1052-1056.
  • 5Claeys R,Vinken S,Spapen H,etal. Plasma procalcitonin and C- reactive protein in acute septic shock: clinical and biological corerlates[J]. Crit Care Med, 2002,30(4) :757-762.
  • 6Haweky PM. Mechanisms of resistance to antibiotics[J]. In tensiev Caer Med, 2000,26 : 9 -13.
  • 7Reinhart K,Meisner M.Biomarkers in the critically ill patient:procalcitonin[J].Crit Care Clin,2011,27(2):253-263.
  • 8Braithwaite S.Procalcitonin:new insights on regulation andorigin[J].Crit Care Med,2000,28(2):586-588.
  • 9Becker K L,Snider R,Nylen E S,et al.Procalcitonin assay insystemic inflammation,infection,and sepsis:clinical utility andlimitations[J].Crit Care Med,2008,36(3):941-952.
  • 10Riedel S,Melendez J H,An A T,et al.Procalcitonin as amarker for the detection of bacteremia and sepsis in theemergency department[J].Am J Clin Pathol,2011,135(2):182-189.

共引文献302

同被引文献41

  • 1董海新,曹震.血浆脂多糖检测与血液细菌培养结果关系探讨[J].医学检验与临床,2010(4):11-12. 被引量:2
  • 2Laura Peran,Desiree Camuesco,Monica Comalada,Ana Nieto,Angel Concha,Maria Paz Diaz-Ropero,Monica Olivares,Jordi Xaus,Antonio Zarzuelo,Julio Galvez.Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis[J].World Journal of Gastroenterology,2005,11(33):5185-5192. 被引量:17
  • 3Xavier RJ, Podolsky DK. Unravealing the pathogenesis ofinflammatory bowel disease[J]. Nature, 2010, 448(7152) : 427-434.
  • 4Xu D,Yu H,Yu Q, et al. Salvia miltiorrhiza increases theexpression of transcription factor Foxp3 in experimental murinecolitis[J], Mol Med Rep,2014,9(5) : 1947-1951.
  • 5Takaishi H,Matsuki T, Nakazawa A, et al. Imbalance inintestinal microflora constitution could be involved in thepathogenesis of inflammatory bowel disease [J]. Int J MedMicrobiol,2008,298(5/6) :463-472.
  • 6Taurog JD, Richardson JA, Croft JT, et al. The germfree stateprevents development of gut and joint inflammatory disease inHLA-B27 transgenic rats[J]. J Exp Med* 1994? 180( 6> : 2359-2364.
  • 7Klement E,Lysy J, Hoshen M, et al. Childhood hygiene isassociated with the risk for inflammatory bowel disease: apopulation-based study[J]. Am J Gastroenterol, 2008? 103(7):1775-1782.
  • 8Poltorak A, He X,Smirnova I,et al. Defective LPS signalingin C3H / He J and C57BL/10 ScCr mice: mutations in Tlr4gene[J]. Science,1998,282(4):2085-2088.
  • 9Danese S. Mechanisms of action of infliximab in inflammatorybowel disease: an anti-inflammatory multitasker [J]. Dig LivDis,2008,40(Suppl 2) :S225-S228.
  • 10Klotz U,Teml A, Schwab M, Clinical pharmacokinetics anduse of infliximab [J ]. Clin Pharmacokinet, 2007, 46(8): 654-.

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部